 |
|
|
|
|
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
SELLAS Life Science Group, Inc.
| | | | | Year Established: | 2012 | | Ticker: | SLS | | Exchange: | NASDAQ | | Main Contact: | Angelos M. Stergiou, MD, SCD h.c., CEO | | | | Other Contacts: | Barbara A. Wood, Executive VP & General Counsel
Leonore C. Witchey-Lakshmanan, Ph.D., Head, Biologics CMC
Laura M. Katz, MPH, Director, Clinical Operations & Biostatistics
Andres A. Gutierrez, MD, Ph.D., CMO
Gregory M. Torre, Ph.D., JD, Chief Regulatory Officer & VP, Operations
Angelos M. Stergiou, MD, CEO & Chairman
| | | | Company Description | | SELLAS Life Science, formerly Galena Biopharma, Argonaut Pharmaceuticals and RXi Pharmaceuticals, is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company’s lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. Galinpepimut-S is poised to enter pivotal Phase 3 clinical trials in patients with AML and Mesothelioma in the first and second half of 2017, respectively. | |
|
|
|
|
|
|
|
